180 related articles for article (PubMed ID: 29769179)
1. RNA Profiles of Circulating Tumor Cells and Extracellular Vesicles for Therapy Stratification of Metastatic Breast Cancer Patients.
Keup C; Mach P; Aktas B; Tewes M; Kolberg HC; Hauch S; Sprenger-Haussels M; Kimmig R; Kasimir-Bauer S
Clin Chem; 2018 Jul; 64(7):1054-1062. PubMed ID: 29769179
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Multi-Parametric Liquid Biopsy Approach Identifies Unique Features of Circulating Tumor Cell, Extracellular Vesicle, and Cell-Free DNA Characterization for Disease Monitoring in Metastatic Breast Cancer Patients.
Keup C; Suryaprakash V; Storbeck M; Hoffmann O; Kimmig R; Kasimir-Bauer S
Cells; 2021 Jan; 10(2):. PubMed ID: 33494385
[TBL] [Abstract][Full Text] [Related]
3. Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment.
Bredemeier M; Edimiris P; Tewes M; Mach P; Aktas B; Schellbach D; Wagner J; Kimmig R; Kasimir-Bauer S
Oncotarget; 2016 Jul; 7(27):41677-41690. PubMed ID: 27223437
[TBL] [Abstract][Full Text] [Related]
4. Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance.
Apostolaki S; Perraki M; Pallis A; Bozionelou V; Agelaki S; Kanellou P; Kotsakis A; Politaki E; Kalbakis K; Kalykaki A; Vamvakas L; Georgoulias V; Mavroudis D
Ann Oncol; 2007 May; 18(5):851-8. PubMed ID: 17301075
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer.
Onstenk W; Sieuwerts AM; Weekhout M; Mostert B; Reijm EA; van Deurzen CH; Bolt-de Vries JB; Peeters DJ; Hamberg P; Seynaeve C; Jager A; de Jongh FE; Smid M; Dirix LY; Kehrer DF; van Galen A; Ramirez-Moreno R; Kraan J; Van M; Gratama JW; Martens JW; Foekens JA; Sleijfer S
Cancer Lett; 2015 Jun; 362(1):36-44. PubMed ID: 25797316
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
7. Molecular detection of peripheral blood breast cancer mRNA transcripts as a surrogate biomarker for circulating tumor cells.
Lasa A; Garcia A; Alonso C; Millet P; Cornet M; Ramón y Cajal T; Baiget M; Barnadas A
PLoS One; 2013; 8(9):e74079. PubMed ID: 24058517
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients.
Zhao S; Yang H; Zhang M; Zhang D; Liu Y; Liu Y; Song Y; Zhang X; Li H; Ma W; Zhang Q
Cell Biochem Biophys; 2013 Mar; 65(2):263-73. PubMed ID: 22990361
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of circulating tumour cells identifies predictive markers for outcome in primary, triple-negative breast cancer patients.
Bittner AK; Keup C; Hoffmann O; Hauch S; Kimmig R; Kasimir-Bauer S
J Cell Mol Med; 2020 Aug; 24(15):8405-8416. PubMed ID: 32558176
[TBL] [Abstract][Full Text] [Related]
10. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
[TBL] [Abstract][Full Text] [Related]
11. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
[TBL] [Abstract][Full Text] [Related]
12. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.
Wülfing P; Borchard J; Buerger H; Heidl S; Zänker KS; Kiesel L; Brandt B
Clin Cancer Res; 2006 Mar; 12(6):1715-20. PubMed ID: 16551854
[TBL] [Abstract][Full Text] [Related]
13. Detection of circulating tumor cells in breast cancer patients using multiplex reverse transcription-polymerase chain reaction and specific primers for MGB, PTHRP and KRT19 correlation with clinicopathological features.
Skondra M; Gkioka E; Kostakis ID; Pissimissis N; Lembessis P; Pectasides D; Koutsilieris M
Anticancer Res; 2014 Nov; 34(11):6691-9. PubMed ID: 25368276
[TBL] [Abstract][Full Text] [Related]
14. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
Kasimir-Bauer S; Bittner AK; König L; Reiter K; Keller T; Kimmig R; Hoffmann O
Breast Cancer Res; 2016 Feb; 18(1):20. PubMed ID: 26868521
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of circulating tumor cells (CTCs) in Egyptian non-metastatic colorectal cancer patients: A comparative study for four different techniques of detection (Flowcytometry, CellSearch, Quantitative Real-time PCR and Cytomorphology).
Bahnassy AA; Salem SE; Mohanad M; Abulezz NZ; Abdellateif MS; Hussein M; Zekri CAN; Zekri AN; Allahloubi NMA
Exp Mol Pathol; 2019 Feb; 106():90-101. PubMed ID: 30578762
[TBL] [Abstract][Full Text] [Related]
16. Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.
Mikulová V; Cabiňaková M; Janatková I; Mestek O; Zima T; Tesařová P
Scand J Clin Lab Invest; 2014 Mar; 74(2):132-42. PubMed ID: 24350991
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy.
Aaltonen KE; Novosadová V; Bendahl PO; Graffman C; Larsson AM; Rydén L
Oncotarget; 2017 Jul; 8(28):45544-45565. PubMed ID: 28489591
[TBL] [Abstract][Full Text] [Related]
18. Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer.
Soekmadji C; Corcoran NM; Oleinikova I; Jovanovic L; ; Ramm GA; Nelson CC; Jenster G; Russell PJ
Prostate; 2017 Oct; 77(14):1416-1423. PubMed ID: 28856701
[TBL] [Abstract][Full Text] [Related]
19. Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer.
Georgoulias V; Apostolaki S; Bozionelou V; Politaki E; Perraki M; Georgoulia N; Kalbakis K; Kotsakis A; Xyrafas A; Agelaki S; Mavroudis D
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1217-25. PubMed ID: 25344760
[TBL] [Abstract][Full Text] [Related]
20. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
Koyanagi K; O'Day SJ; Gonzalez R; Lewis K; Robinson WA; Amatruda TT; Wang HJ; Elashoff RM; Takeuchi H; Umetani N; Hoon DS
J Clin Oncol; 2005 Nov; 23(31):8057-64. PubMed ID: 16258104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
